Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12227664 | 0.97 | MEN1 (0.36) | MEN1KMT2AGALR3TP53CYP1A2 | |
| SCHEMBL10036511 | 0.83 | MEN1 (0.34) | MEN1KMT2AGALR3TP53CYP1A2 | |
| SCHEMBL10036514 | 0.79 | SPHK1 (0.31) | MEN1KMT2AGALR3TP53CYP1A2 | |
| SCHEMBL7910571 | 0.76 | ACE (0.46) | MAPT | |
| SCHEMBL7916721 | 0.74 | SMN1; SMN2 (0.35) | MEN1KMT2ATP53CYP1A2CYP2D6 | |
| SCHEMBL10036499 | 0.73 | MEN1 (0.35) | MEN1KMT2AGALR3TP53CYP1A2 | |
| SCHEMBL10067468 | 0.72 | ACE (0.50) | MAPTCYP2C19 | |
| SCHEMBL7924504 | 0.72 | ACE (0.50) | MAPTCYP2C19 | |
| SCHEMBL10036509 | 0.72 | SIGMAR1 (0.49) | MEN1KMT2AGALR3CYP2C9 | |
| SCHEMBL12227668 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | MEN1 1876/4885KMT2A 3405/4885GALR3 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.